ReviewObesity surgery2026
Tranexamic Acid Administration in Laparoscopic Sleeve Gastrectomy.
Review in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimPerioperative bleeding remains one of the most frequent early complications of laparoscopic sleeve gastrectomy (LSG). The present work aimed to provide a thorough and updated systematic review and meta-analysis of the published studies on the use of tranexamic acid (TXA) in LSG.
methodsThe present study was conducted according to the Preferred Reporting Items for Systematic review and Meta-Analyses (PRISMA) guidelines. A systematic literature search was conducted in PubMed, Scopus, and Web of Science.
resultsThe present study analyzed 9 studies. They included 1665 patients. TXA was administered to 842 patients while 823 patients received no intervention or placebo. Pooled analysis revealed significantly shorter operative duration [mean difference (95% CI): -4.56 (-7.36, -1.76), p = 0.001], shorter length of hospital stay [mean difference (95% CI): -0.12 (-0.16, -0.08), p<0.00001] and lower reduction of preoperative hemoglobin levels in the TXA arm [mean difference (95% CI): -0.2 (-0.38, -0.02), p = 0.03]. No significant differences were found between the interventional arms regarding number of used intraoperative hemostatic clips [mean difference (95% CI): -0.2 (-0.93, 0.53), p = 0.59], number of patients requiring blood transfusion [RD (95% CI): -0.01 (-0.02, 0.0), p = 0.08] or number of patients requiring reoperation for bleeding [RD (95% CI): -0.01 (-0.03, 0.0), p = 0.12]. No thromboembolic events were reported.
conclusionsThe present study suggests that, based on the currently available evidence, intraoperative administration of TXA is associated with lower reduction of preoperative hemoglobin levels in patients undergoing LSG, which may contribute to shorter operative duration and reduced length of hospital stay.
Indexed as
Identifiers
42711637What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.